AbbVie price target raised to $227 from $216 at Guggenheim

Guggenheim raised the firm’s price target on AbbVie (ABBV) to $227 from $216 and keeps a Buy rating on the shares following what the firm calls “another strong quarter.” Management raised full-year revenue and EPS guidance for the second time this year, adds the analyst, who update the firm’s model to reflect higher Skyrizi and neuroscience estimates, a steeper Humira erosion curve, and slightly lower aesthetics estimates.